Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B. Johnson, Javid J. Moslehi, Justin M. Balko et al.|New England Journal of Medicine|2016Cited by 2.3k
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyDouglas B. Johnson, Justin M. Balko, Mónica V. Estrada et al.|Nature Communications|2016Cited by 572
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B. Johnson, Christine M. Lovly, Erik Yusko et al.|Cancer Immunology Research|2016Cited by 493
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B. Johnson, Justin M. Balko|JCI Insight|2018Cited by 159
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150